U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07399977) titled 'Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism' on Feb. 03.
Brief Summary: The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.
Study Start Date: Jan. 30
Study Type: INTERVENTIONAL
Condition:
Venous Thromboembolism
Deep Venous Thrombosis
Intervention:
DIAGNOSTIC_TEST: MSK-ACCESS
MSK-ACCESS is a ctDNA sequencing assay
DIAGNOSTIC_TEST: ctDNA/VTE Risk Score:
Machine learning Venous Thromboembolism/VTE risk scor...